|
|
Vaccine Detail
|
Recombinant dHER2 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant dHER2 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007014
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: ERBB2
- ERBB2
gene engineering:
- Preparation: Each dose of dHER2 immunotherapeutic contains 500 lg of dHER2, a fusion protein including the complete extracellular domain (ECD) and a truncated part of the intracellular domain (ICD) of the HER2 protein plus a fixed dose of AS15 (Curigliano et al., 2016).
- Description: This is for Breast Cancer (NCT00140738). A cancer vaccine consisting of a truncated recombinant HER2 peptide (dHER2) with potential antineoplastic activity. Upon administration, recombinant dHER2 vaccine may stimulate the host immune response to mount a cytotoxic T-lymphocyte response against tumor cells that overexpress the HER2 protein, resulting in tumor cell lysis. The HER2 protein is a tumor-associated antigen (TAA) that is overexpressed in a variety of cancers. dHER2 includes the extracellular domain (ECD) and a part of the intracellular domain (ICD) of the HER2 protein. (NCIT_C49177).
|
| Host Response |
|
|
| References |
Curigliano et al., 2016: Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. Breast cancer research and treatment. 2016; 156(2); 301-310. [PubMed: 26975189].
NCIT_C49177: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49177]
NCT00140738: [https://clinicaltrials.gov/show/NCT00140738/]
|
|
